Bristol-Myers Squibb (BMY) is transforming itself into a more powerful biopharmaceutical company through the acquisition of Celgene (CELG). Although the stock gained about 21% since the merger was announced in January 2019, the valuation is still lower than many of the company's peers and the Major Drug Manufacturing industry as a whole.
It appears that the Celgene acquisition might not be fully reflected in the stock price. Investors could be skeptical of how large an impact the acquisition will be for Bristol-Myers. The skepticism could also be the result of not